Latest Lakewood-Amedex Biotherapeutics News & Updates

See the latest news and media coverage for Lakewood Amedex. We track all announcements, press releases, and industry mentions in real time, all in one place.

Lakewood-Amedex Biotherapeutics (Lakewood Amedex)

Antimicrobial drug developer

lakewoodamedex.com

Headquarters: University Park, United States
Company type: Public company
Number of employees: 5–10
Industry: Pharmaceuticals

Last updated Today

Latest news about Lakewood-Amedex Biotherapeutics (Lakewood Amedex)

In short: Lakewood Amedex advanced its lead antimicrobial candidate Nu-3 and expanded its IP portfolio to combat antibiotic-resistant infections.

Company announcements

July 22 Lakewood Amedex

Lakewood-Amedex highlights Nu-3 resistance data in response to PACCARB

Nu-3 targets bacterial membranes with a high barrier to resistance, supporting the national action plan against antibiotic-resistant bacteria.

July 15 Lakewood Amedex

Lakewood-Amedex announces preclinical safety data for Nu-3 gel

The data supports dose selection for an upcoming Phase 2a trial in infected diabetic foot ulcers.

July 7 Lakewood Amedex

Lakewood-Amedex Biotherapeutics supports PASTEUR Act reintroduction

The company highlights its Bisphosphocin platform and lead candidate Nu-3 for combating antimicrobial resistance.

June 25 Lakewood Amedex

Lakewood-Amedex announces David Armstrong as Study Chair for Nu-3 trial

Dr. Armstrong will lead Phase 2a trial for infected diabetic foot ulcers.

Media coverage

August 17 Stock Titan

Lakewood-Amedex flags going concern risk | LABT Prospectus Summary

Lakewood-Amedex Biotherapeutics Inc. (“Lakewood-Amedex” or the “Company”) is a Nevada corporation headquartered in University Park, Florida. The Company was originally incorporated on July 11, 2006...

June 25 Morningstar

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

SARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials...

May 1 Nasdaq

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers

SARASOTA, Fla., May 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials...

April 23 Barron's

Lakewood-Amedex Biotherapeutics Inc.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...

Never miss news about Lakewood Amedex

Track Lakewood Amedex and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.